RetinoRx

RetinoRx is a preclinical-stage biotechnology company focused on developing novel small molecule therapeutics for blinding retinal degenerative diseases. The company's primary focus is on geographic atrophy (GA) and dry age-related macular degeneration (dry AMD), conditions characterized by the progressive loss of retinal pigment epithelial (RPE) cells. Founded by Dr. Robert Bhisitkul, a leading ophthalmology researcher at UCSF, RetinoRx leverages proprietary insights into retinal biology to advance its lead program. This program targets the complement system to prevent the cellular atrophy that leads to irreversible vision loss. The company aims to address a significant unmet medical need in the ophthalmic space by providing a first-in-class treatment option. RetinoRx is headquartered in San Francisco, California.